Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | ACACA | Q13085 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | SELL | P14151 | 7/20 | 0.43 |
| ▸ | SELP | P16109 | 7/20 | 0.43 |
| ▸ | SELE | P16581 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68973 | 0.85 | HPGD (0.59) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL5663464 | 0.84 | ACACA (0.60) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL13088311 | 0.83 | DPP4 (0.62) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL5263932 | 0.81 | APP (0.55) | RPS6KB2HPGDKMT2AACACASELL | |
| SCHEMBL11083765 | 0.79 | HPGD (0.58) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL26038966 | 0.79 | MAPT (0.51) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL20772791 | 0.79 | RAB9A (0.47) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL5663442 | 0.78 | RPS6KB2 (0.49) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL20796117 | 0.78 | ACACA (0.50) | RPS6KB2HPGDKMT2AACACAMAPT | |
| SCHEMBL20796127 | 0.78 | ACACA (0.50) | RPS6KB2HPGDKMT2AACACAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9359311-B2 | Substituted aromatic oligomers | NEUROSCIOS GMBH (AT) | 2016-06-07 | — | — | US | disclosed |
| US-9334304-B2 | Self-assembling peptides bearing organic electronic functionality and applications employing the same | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334304-B2 | Self-assembling peptides bearing organic electronic functionality and applications employing the same | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334304-B2 | Self-assembling peptides bearing organic electronic functionality and applications employing the same | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2817304-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BioChromix NewCo AB (SE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2014-05-15 | — | — | US | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036196-A1 | NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009259-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | BIOCHROMIX PHARMA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120101022-A1 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101022-A1 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101022-A1 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010115080-A2 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135322-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | PRNP, TBCA, HSPA5 | RPS6KB2 1821/4885HPGD 4032/4885KMT2A 4329/4885 |
| US-20120101022-A1 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME | APP, IAPP, DNPEP | RPS6KB2 4788/4885HPGD 2417/4885KMT2A 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.